The Street Is Finally Waking Up To Arbutus Biopharma Corp (NASDAQ: ABUS)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Arbutus Announces 2024 Corporate Objectives and Provides Financial Update.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Arbutus Biopharma Corp is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $2.47 and fluctuated between $2.4700 as its day high and $2.3500 as its day low. The current market capitalization of Arbutus Biopharma Corp is $414.19M. A total of 0.71 million shares were traded on the day, compared to an average of 773.86K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ABUS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.

In the most recent transaction, McElhaugh Michael J. sold 10,164 shares of ABUS for 2.31 per share on Feb 02. After the transaction, the Interim President & CEO now owns 1,504,793 company shares. In a previous transaction on Feb 02, Sofia Michael J. sold 9,982 shares at 2.31 per share. ABUS shares that Chief Scientific Officer owns now total 1,485,121.

Among the insiders who sold shares, HASTINGS DAVID C disposed of 9,593 shares on Feb 02 at a per-share price of $2.31. This resulted in the Chief Financial Officer holding 181,907 shares of ABUS after the transaction. In another insider transaction, Sims Karen sold 4,358 shares at $2.31 per share on Feb 02. Company shares held by the Chief Medical Officer now total 125,542.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ABUS in the last 3 months, the mean price target is $4.60 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, ABUS has a high of $3.14 and a low of $1.69.

As of this writing, ABUS has an earnings estimate of $Arbutus Biopharma Corporation per share for the current quarter. EPS was calculated based on a consensus of Alpha Blue Capital US Small-Mid estimates, with a high estimate of $Acumen Pharmaceuticals, Inc. per share and a lower estimate of $Altice USA, Inc.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.71, while its Total Shareholder’s Equity was $169.44M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.

Most Popular

Related Posts